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Objective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants
with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23+0 to 26+6
weeks) receiving 200mg/kg surfactant (curosurf) within ﬁve minutes after birth (prophylactic group, N = 31) with those infants
whoreceivedsurfactanttherapyforestablishedRDS(selectivegroup,N = 34).Results.Prophylactictherapysigniﬁcantlydecreased
the need for mechanical ventilation (74hours per patient versus 171 hours per patient, resp.). We observed a reduced incidence
of interstitial emphysema (0% versus 9%, resp.), pneumothoraces (3% versus 9%, resp.), chronic lung disease (26% versus 38%,
resp.), and surfactant doses per patient (1.3 versus 1.8, resp.), although those variables did not reach signiﬁcance. Conclusion.
We conclude that infants under 27 weeks’ gestation proﬁt from prophylactic surfactant administration by reducing the time of
mechanical ventilation. This in turn could contribute to reduce the risk for mechanical ventilation associated complications,
without any detrimental short-term side eﬀects.
1.Introduction
Evidence from randomized, controlled trials, as summarized
in the Cochrane systematic reviews, demonstrates that
prophylactic surfactant administration to infants judged to
be “at risk” for developing respiratory distress syndrome,
compared to selective use of surfactant in infants with
established RDS, improved outcomes for high-risk preterm
infants [1]. The use of surfactant for the treatment or
prophylaxis of neonatal RDS results in a 30–65% relative
reduction in the risk of pneumothorax and up to a 40%
relative reduction in the risk of mortality. Adverse events
are infrequent, and long-term follow-up studies are reas-
suring. Prophylactic administration of surfactant may be
preferable to rescue treatment, especially in infants <30
weeks of gestation, as it decreases the risk of pneumothorax,
pulmonary interstitial emphysema, and neonatal mortality
[2], but may result in some babies being intubated and
receiving therapy unnecessarily. These trials were carried out
in the early 1990s when prenatal steroids were used less than
currently and the respiratory assistance with noninvasive
nasalcontinuouspositiveairwaypressure(CPAP)waspoorly
adopted in very preterm infants. Nasal CPAP is currently
a ﬁrst-line technique of respiratory support in newborns,
and its use as an alternative to intubation and mechanical
ventilation, also in extremely low gestational age infants, is
well documented [3, 4], but no clinical trial compared initial
CPAP and rescue surfactant therapy with initial intubation
and prophylactic surfactant administration. Therefore, it
remains unclear which criteria should be used to select
“at risk” infants who would require prophylactic surfactant
administration.
In our retrospective analysis, we based our comparison
of prophylactic with selective surfactant treatment on the
hypothesis that infants under 27 weeks’ gestation are “at
risk” in developing RDS and may proﬁt from prophylactic
surfactant administration.
2. Methods
Preterm infants with a gestational age between 23 + 0 and
26+6weeks+daysborninourcenterduringtheobservation2 Critical Care Research and Practice
periodfromJanuary2007toDecember2007wereeligiblefor
the study.
Infants included in the study received 200mg∗kg
−1 of a
naturalsurfactantpreparation(curosurf,Chiesi,German y)
via intratracheal tube within ﬁve minutes after birth. The
outcome criteria were compared with a historical control
group of patients treated in the 12 months immediately
before the observational period. These control infants were
treated with CPAP at 5-6cm H2O and were intubated and
received surfactant therapy only for established RDS FiO2 >
0.4 to maintain SpO2 between 85% and 93%). Infants who
needed tracheal intubation and mechanical ventilation for
primary resuscitation received surfactant within 20 minutes
after birth. In both study groups, infants were extubated
as soon as FiO2 < 0.3 and a mean airway pressure <7cm
H2O was reached. Immediately after extubation, CPAP at
5-6cm H2O was started using a stephanie respirator. CPAP
was discontinued when the neonate remained stable with
PCO2, oxygen saturation, and no CPAP for more than
four consecutive hours. No other changes in intensive care
management occurred during the study period.
Outcome criteria such as chronic lung disease (CLD),
deﬁnedastheneedofadditionaloxygenafter36weeksgesta-
tionalage,intraventricularhemorrhage(IVH)>IIaccording
to the classiﬁcation of Papile, periventricular leukomalacia
(PVL), pulmonary interstitial emphysema (PIE), patient
ductus arteriosus (PDA), rate of nosocomial infection,
usage of postnatal steroids (hydrocortisone), and necrotizing
enterocolitis (NEC) stadium II or III according to Bell are
also reported.
Echocardiographic criteria for treatment of PDA in-
cluded an increased left atrial diameter compared with aortic
root (ratio> 1.2), visualization of the ductus (>2mm), and
evidence of left-to-right blood ﬂow through the open duct
as summarized by Sperandio et al. [5]. Nosocomial infection
was deﬁned according to NEO-KISS criteria. It is based on
the US Centers for Disease Control and Prevention (CDC)
criteria and has been adapted for this speciﬁc age group
[6].
Postnatalsteroidtherapywithhydrocortisonewasstarted
when the postnatal age was >1 week and the children was
ventilator-dependent with increasing oxygen requirements
or needed oxygen >40% on CPAP or oxygen cannula. Infants
received hydrocortisone according to a well established nine-
day protocol: 3 days 45mg/m2/d (∼4-5mg/kg), tapered to
30mg/m2/d (∼3mg/kg) for another 3 days followed by
15mg/m2/d (∼1-2mg/kg) for 3 days, given 3 times a day
according to the circadian rhythm.
The study was carried out in accordance with ethical
guidelines for human studies.
3. Statistics
Data are given as mean and range or number (percentage)
andwereanalyzedwithSPSSsoftware(SPSSforMac,version
16.0, Chicago, IL). The baseline characteristics of the two
groups were compared using Student’s t-test for parametric
and the chi-squared test for nonparametric comparisons. P-
values <. 05 were considered statistically signiﬁcant.
4. Results
Thirty-one infants with a gestational age between 23+0 and
2 6+6w e e k s+d a y sw e r eb o r na n dt r e a t e di no u rc e n t e r
during the observational period of 12 months. There were
no signiﬁcant diﬀerences between birthweight, gestational
age, sex, use of antenatal steroids, APGAR-score, rate of
SGA (small for gestational age, birth weights below 10th
percentile), and rate of multiple births of all patients treated
in the observational period and historical control period as
Table 1 shows. In each group, one patient suﬀered from
serious hydrops fetalis. Twin to twin transfusion appeared in
one twin birth in each group. Furthermore, in the selective
surfactant group one patient had unknown trisomy 18.
Table 2 shows the mortality and morbidity rates for
all patients of the prophylactic and selective surfactant
group. Prophylactic surfactant therapy was associated with
improved respiratory outcome. The duration of mechanical
ventilation was tremendously and signiﬁcantly shorter in
the prophylactic surfactant group compared to the selective
surfactant group (74 hours per patient versus 171 hours per
patient, resp.). In addition, we found a reduced incidence
of PIE (0% versus 9%, resp.), pneumothoraces (3% versus
9%,resp.),andCLD(26%versus38%,resp.),althoughthose
variables did not reach signiﬁcance.
Therewerenodiﬀerencesbetweendiagnosis(71%versus
82%, resp.) and treatment (68% versus 68%, resp.) of PDA
and nosocomial infections (45% versus 44%, resp.). The
incidence of NEC stadium II or III according to Bell was
increased in the selective surfactant group (3% versus 15%,
resp.), although this variable did not reach signiﬁcance.
The use of postnatal steroids was not diﬀerent in both
groups (61% versus 62%, resp.). Interestingly, we found a
decreased number of surfactant doses used per patient in the
prophylactic group (1.3 versus 1.8, resp.).
5. Discussion
Recent randomized and controlled trials demonstrated that
prophylactic or early surfactant as compared to delayed
rescue surfactant treatment results in improved outcomes
for high-risk preterm infants [1, 7, 8]. However, the trials
did not provide a deﬁnitive answer to the question of
best timing of surfactant application at diﬀerent gestational
ages. Moreover, these data have been obtained in the early
1990s when prenatal steroids were used less than currently
and the respiratory assistance with noninvasive nasal CPAP
was poorly adopted in very preterm infants. Despite the
advantages of prophylactic surfactant strategy for infants
born less than 30 weeks’ gestation, many such infants treated
only after RDS has become established. In a large North
American cohort of 47608 infants less than 30 weeks of
gestation born between 1998 and 2000, only 27% received
surfactant in the delivery room and 44% received surfactant
b y3 0m i n u t e so fa g e .E v e nl a t e r ,( b e f o r e6h o u r so fa g e )
still 29% had been given surfactant [9]. In the group of
infants with gestational age less than 27 weeks, only 32%
received surfactant in the delivery room. The European con-
sensus guidelines now recommend a prophylactic surfactantCritical Care Research and Practice 3
Table 1: Patients’ characteristics.
Prophylactic surfactant group
(observational period) n = 31
Selective surfactant group
(historical control) n = 34
Signiﬁcance
Birthwight (g) 709 ±164 701 ±159 n.s.
Gestational age (wks+d) 25+1(23+1t o26+6) 25+3(23+1t o26+5) n.s.
Male sex (%) 54 41 n.s.
Antenatal steroids (%) 90 91 n.s.
APGAR-Score (5 minutes) 77 n.s.
SGA (%) 29 15 n.s.
Multiple births (%) 79 n.s.
GA < 24 wks (%) 19 18 n.s.
SGA:small for gestational age (birth weights below 10th percentile); GA:gestational age; wks, weeks; d, days.
Table 2: Mortality and morbidity.
Prophylactic surfactant group
(observational period) n = 31
selective surfactant group
(historical control) n = 34
Signiﬁcance
Death until term 5 (16%) 6 (18%) n.s.
IVH> II 4 (13%) 3 (9%) n.s.
PVL 3 (10%) 1 (3%) n.s.
Pneumothorax 1( 3 % ) 4( 9 % ) n.s.
CLD 8 (26%) 13 (38%) n.s.
PIE 0( 0 % ) 3( 9 % ) n.s.
Need for mechanical ventilation (h per patient) 74 ±26 171 ±35 P = .03
Diagnosis of PDA 22 (71%) 28 (82%) n.s.
Treatment of PDA 21 (68%) 26 (68%) n.s.
NEC 1 (3%) 5 (15%) n.s.
Nosocomial infection 14 (45%) 15 (44%) n.s.
Postnatal steroids 19 (61%) 21 (62%) n.s.
Surfactant doses 41 62 n.s.
Surfactant doses per patient 1.3 1.8 n.s.
IVH:intraventricular hemorrhage; PVL:periventricular leukomalacia; CLD:chronic lung disease (need of additional oxygen after 36 weeks gestational age);
PIE:pulmonary interstitial emphysema; PDA:patient ductus arteriosus; NEC:necrotizing enterocolitis (stadium II or III according to Bell).
therapy within 15 minutes of birth to almost all babies
under 27 weeks’ gestation [10]. In our study, we address the
questionwhetherthis strategy improves respiratory outcome
in very premature infants under 27 weeks’ gestation.
According to other studies [1, 7], we found a reduced
incidence of pulmonary interstitial emphysema and pneu-
mothoraces, although those variables did not reach signif-
icance. The risk of developing chronic lung disease after
prophylactic surfactant compared with rescue surfactant
has been discussed and remains controversial. Secondary
analyses of clinical trials reported no diﬀerent [1], decreased
[11–13], and increased [14] risk of CLD in preterm infants
who received prophylactic surfactant compared with those
who received later selective surfactant treatment. Reininger
et al. [15] compared the eﬀect of one dose of intratracheally
administered surfactant followed by extubation to nasal
CPAP with nasal CPAP alone in infants 29 to 35 weeks’
gestation with mild-to-moderate RDS requiring supplemen-
tal oxygen and NCPAP. 57% of the infants in the control
groupand46%oftheinfantsinthesurfactantgroupreceived
antenatal steroids. Reininger et al. showed a signiﬁcantly
decreased need for mechanical ventialtion with the use of
prophylacticsurfactantadministrationandidentiﬁedatrend
toward a decrease in the incidence of bronchopulmonary
dysplasia (BPD).
In line with these studies, we also observed a trend to a
decreasedincidenceofchroniclungdisease.Nevertheless,the
signiﬁcant shortening of the time of mechanical ventilation
turned out to be the most dramatic result of our study. This
in turn could contribute to reduce the risk for mechanical
ventilation associated complications.
Nasal CPAP is currently a ﬁrst-line technique of respi-
ratory support in newborns, and its use as an alternative
to intubation and mechanical ventilation, also in extremely
low gestational age infants, is well documented [3, 4]. Few
randomized trials have compared diﬀerent approaches of
intubation with surfactant administration and mechanical
ventilation versus early nasal CPAP. The results of these
studies did not highlight signiﬁcant diﬀerences [16–18].
Morley et al. [17] compared initial CPAP (8cm H2O) with
initial intubation in the delivery room in infants 25 to 28
weeks of gestational age (COIN trial). They found a better4 Critical Care Research and Practice
outcome at 28 days in the CPAP group compared to the
intubation group; the two groups had a similar outcome
at 36 weeks’ gestational age. Early nasal CPAP did not
signiﬁcantly reduce the rate of death or bronchopulmonary
dysplasia, as compared with intubation. The beneﬁts of
CPAP included a lower risk of combined outcome of death
or the need for oxygen therapy at 28 days and fewer
days of assisted ventilation. There is no information about
the days of assisted ventilation in the CPAP subgroup of
infants at 25 or 26 weeks’ of gestation. In contrast, we
found a signiﬁcant decrease in the need for mechanical
ventilation after intubation and prophylactic surfactant
administration. In the COIN trial, sick infants who required
immediateintubationwereexcludedandtiming,dosing,and
preparation of surfactant were not mandated and followed
local protocols. The death rate at day 28 in the CPAP
subgroup of infants at 25 or 26 weeks’ of gestation was more
than twice as high as in the intubation group (odds ratio
2.04; 95% CI 0.72–5.74), but this failed to meet statistical
signiﬁcance.
Verder et al. [19, 20] showed a low mortality and low
morbidity when INSURE method (intubation-surfactant
treatment-extubation) was used for treatment of very pre-
mature infants with RDS. Taken together, there is increasing
evidence suggesting intubation and prophylactic administra-
tion of surfactant in extremely premature infants.
There are many pathophysiologic reasons why prophy-
lactic surfactant therapy might be more eﬀe c t i v ea n dl e a dt o
less lung injury than late surfactant therapy for established
RDS. In a surfactant-deﬁcient lung of an air-breathing
animal, there is ongoing leakage of serum proteins into
alveolar space. These proteins act as inhibitors of surfactant
function [21]. Jobe et al. [22] and Ikegami et al. [23]h a v e
demostrated that early exogenous surfactant administration
can reduce the protein leak, and others have shown that early
administration of surfactant can lower severe lung injuries in
RDS [24, 25].
6. Conclusion
From our data we conclude that infants under 27 weeks’
gestation are “at risk” in developing RDS and proﬁt from
prophylactic surfactant administration by reducing the time
of mechanical ventilation. This in turn could contribute
to reduce the risk for mechanical ventilation associated
complications (interstitial emphysema, pneumothoraces,
and chronic lung disease) without any detrimental short-
term side eﬀects. As shown in the COIN trial [17], initial
nasal CPAP did not signiﬁcantly reduce the rate of death
or bronchopulmonary dysplasia, as compared with initial
intubation,butcouldincreasethemortalityrateinextremely
preterm infants. Therefore, we consider that it is safer to
intubate these smallest babies and administer prophylactic
surfactant.
Due to the retrospective nature and the small sample
size of our clinical trial more prospective, randomized and
controlled trials (like the forthcoming report on the NICHD
Neonatal Research Network SUPPORT trial [26] and the
CURPAP study [27]) are needed to test whether prophylactic
surfactant administration in very preterm infants is superior
over the selective procedure.
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